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Introduction 
Excessive accumulation of one or more of the major lipids in plasma can produce a marked increase in
the risk of coronaiy heart diseases and other vascular complications. Increased levels of serum total
cholesterol and more specifically low density lipoprotein are a major risk factor for cardiovascular
diseases. There is substantial evidence that appropriate treatment can reduce this risk1,2. Decreased
high density lipoprotein levels are also an important risk faqtor1,2, whereas, the role of increased serum
triglyceride levels as an independent risk factor is still being debated3. The accumulation of one or
more lipoprotein fractions can either be due to defective removal from ‘plasma or increased
endogenous production or both. These mechanistic abnormalities may beprimaiy ormay result
secondary to other diseases such as diabetes mellitus, nephrotic syndrome, uremia, hypothyroidism,
chronic infections, and malignancies4-7. Several commonly used drugs suchasgiucocorticoids, oral
contraceptive pills, thiazide diuretics, beta-blockers and interferons can also produce significant
increase in serum lipoprotein levels7,8. In this review we will briefly describe the physiology and
biochemistry of various lipoproteins and the different causes of hyperlipidernia. We will also provide
an update on the basic principles in the management of hyperlipidemia and the guidelines for the
rational drug therapy in various disorders of lipid and lipoprotein metabolism.
Biochemistry and Physiology of Lipoproteins
Lipoproteins are macromolecular complexes carrying various lipids and proteins in the plasma. The
major lipids of lipoproteins are free and estenfied cholesterol, TGs and phospholipids. Triglycerides
(TO) and cholesterol esters are hydrophobic and constitute the core of lipoproteins. Phospholipids and
free cholesterol, which are soluble in both lipid and aqueous environments, cover the surface of the
lipoproteinparticleswhere they actas aninterfacebetweenthe plasma and core components. In addition to
phospholipids and free cholesterol, there is a group of proteins which also occupy the surface of
lipoproteins and are called apolipoproteins or apoproteins. These apoproteins play an important role in
the regulation of lipid transport and lipoprotein metabolism9. The lipoproteins have been subdivided
into five major classes on the basis of their physical and chemical characteristics as they vary in
density, size, source of origin, lipid composition and function. These classes include chyloniicrons,
very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density
lipoproteins (LDL) and high density lipoproleins (HDL). The major characteristics of these lipoprotein
classes are summarized in Table I.
Triglycerides are the major lipids in chylomiçrons and VLDL. They serve as energy substrates in the
liver and peripheral tissues. Energy is also stored in the form of TGs in the adipose tissue. Most TG
molecules in chylornicron and VLDL are hydrolyzed by lipoproteinlipase (LPL) and hepatic TGlipase
(HTGL). The fatty acids released by these reactions are taken up by the liver, muscle and adipose
tissue. TGs can also be transferred between TG-nch and cholesterol-rich lipoproteins in association
with a carrier protein known as cholesterol ester transfer protein10. Cholesterol is present in all the
lipoproteins but it is the major component of LDL, IDL and HDL. Cholesterol is not used for energy
but it serves as a structural component of all cell membranes. It is also a precursor for adrenal and
gonadal steroids and hepatic bile acids. Inlipoproteinparticles, most of the cholesterol is found in the
form of cholesterol esters in the core. The majorcholesterol ester is cholesterol linoleate which is
formed in the plasma by the action of lecithin cholesterol acyltransferase (LCAT) enzyme. A small
proportion of lipoprotein cholesterol is carried as free cholesterol in the surface of lipoprotein particles.
Phospholipids, which are the component of all cell membranes, make up the majority of surface of
lipoproteins. They form a lipid layer that acts as an interface with both the polar plasma environment
and the non-polar lipids of the lipoprotein core. Phosphotidyicholine (lecithin) is the major
phospholipid in plasma and is the source of linoleate for cholesterol ester formation by LCAT reaction.
Different apoproteins are found on the surface of lipoproteins. In addition to providing structural
stability to lipoproteins, they also have a critical role in the regulation of lipoprotem metabolism9.
Some of them are essential for the synthesis and secretion of chylomicrons and VLDL whereas others
act as ligand for the binding of lipoproteins to their receptors. Some of the apoproteins act as co-factor
for plasma enzymes such as LPL and LCAT. The deficiency or abnormal function of these apoproteins
can result in abnormalities in lipid meabolism11,12.The well characterized apoproteins and their major
metabolic functions are listed in Table II.
Causes of Hyperlipidemia
The intravascular concentrations of various lipoprotein particles orthe concentrations of plasma
lipidsare determined by the balance between the rate of formation of lipoproteins and the rates of their
degradation and/or cellular uptake. Disruption of this balance can lead to hyperlipidemia which may
manifest as hypercholesterolernia or hypertriglyceridemia or a combination of both. The abnormalities
of lipoprotein metabolism may be primary in origin or may occur secondary to other diseases or
therapy with certain drugs or hormones13,14. The primary types of hyperlipidemia are generally divided
into familial and sporadic forms. In familial type there is a clear evidence of genetic predisposition
based on the presence of the disorder in closely related family members whereas in the sporadic variety
no known genetic factor or secondary cause is present. The primary and secondary hyperlipidernia are
generally characterized by similar laboratory abnormalities, however, the magnitude of the changes in
plasma lipid levels may be variable. It is important to differentiate between primary and secondary
hyperlipidemia from a therapeutic point of view, as the secondary hyperlipidemia may be corrected by
treatment of causative disease or by withdrawal of the drug responsible for producing the abnormality.
Classically, hyperlipidemia have been classified into six types on the basis of specific electrophoretic
patterns of various lipoproteins in plasma15. According to this classification the patients with different
disorders of lipid metabolism may have an excess of chylomicrons (type I), elevated LDL (type HA),
or an increase in both LDL and VLDL (Type IIB) levels. In some rare familial disorders there is
excessive accumulation of VLDL remnant particles (type III). Anexcess of VLDL alone (type IV) or
VLDL and chylornicrons(typeV) may also occur in several pr mary and secondary disorders of TG
metabolism. However, studies have shown that these plasma lipoprotein patterns are not specific to
various primary and secondary disorder of lipoprotein metabolism. The plasma lipoprotein patterns
may change overtime in individuals as VLDL is converted to IDL and LDL. Them are also profound
effects of diet on lipoprotein metabolism16. Thus, classificationsbasedonthetype of plasma lipoprotein
patterns may not reflect the genetic or pathophysiologic mechanisms responsible for various disorders.
A single mechanism may lead to several different lipoprotein patterns while a single pattern may result
from a variety of diseases or mechanisms. From a pathophysiologic perspective the disorders of
lipoprotein metabolism may either be due to an increase in endogenous production of lipoproteins or a
defect in their removal or a combination of both mechanisms. Increased endogenous production is
usually due to an increase in hepatic VLDL synthesis and secretion and is commonly seen in familial
hypertriglyceridernia, diabetes mellitus, acromegaly, cushing’s syndrome, chronic alcoholism and
prolonged use of corticosteroids and oral contraceptives13,14 . On the other hand, defective removal of
lipoproteins can occur at three different sites along the lipoproteintransport pathway. It could be due to
a defect in the cellular uptake of LDL secondaiy to a deficiency or absence of LDL receptors, defective
removal of remnant particles due to mutations in apo F gene, or decreased catabolism of TG-rich
lipoprotein due to deficiency or abnormal function of lipoprotein lipase enzyme13,14.
Table III presents a classification of common causes of hyperlipidemia based on the pathophysiologic
mechanism involved.
Management of Hyperlipidemia
In order to treat patients with hyperlipidemia, the therapeutic approach should focus on reducing the
overall cardiovascular risk. After taking a family and personal history of cardiovascular disease, an
effort should be made to identify secondary causes of hyperlipidernia such as inappropriate diet,
uncontrolled diabetes mellitus, undiagnosed or untreated hypothyroidism and drug which may alter
lipid metabolism. Smoking status, exettise level and degree of obesity should also be determined. In
many patients a serious and sincere effort which reduces these risk factors through changes in life style
and therapy of specific diseases can produce a substantial decrease in serum lipid levels, reduce the risk
of cardiovascular diseases and may nepte the need for specific anti-hyperlipidemic drug therapy17. The
first step in the management of hyperlipidemia is usually the nutritional counselling and dietary
therapy18. The patients should be advised to reduce their fat intake to less than 30% of their total
caloric intake and saturated fatty acid should be less than 10% of total caloric intake; the rest of the fat
calories should come from poly-unsaturated and mono-unsaturated fatty acids in a roughly equal ratio.
At this stage, the dietary intake of cholesterol should be less than 300 mg/day. If the serum lipid levels
do not respond to these changes within three months, then a further reduction in total fat intake is
usually necessary. In this dietary regimen saturated fatty acid should constitute less than 7% of total
caloric intake and total cholesterol intake should be less than 200 mg/day. The patients who do not
respond to changes in life style and diet should be treated with specific anti-hyperlipidemic drugs
depending upon their lipid profile. Patients with a history of ischemic heart disease should be
aggressively treated by minimizing other cardiovascular risk factors and maximizing the control of
serum lipoprotein levels. In most cases this approach has been shown to reduce the progression of
atherogenesis and subsequent morbidity and mortality associated with cardiovascular diseases19,20.
Recently specific guidelines have been developed by the Adult Treatment Panel of the National
Cholesterol EducationProgmmme(NCEP)ofUnited States which utilizes LDL levels for assessing the
risk of heart disease and for treatment recommendations21. Similarly specific guidelines for the
management of hypertriglyceridemia have also been developed22. Both of these panels have classified
total cholesterol, LDL-cholesterol and TO levels as desirable, borderline and high risk (Table IV).
A low HDL-cholesterol (<30 mg/dl) is also considered as a major risk factor whereas high HDL-
cholesterol (>60 mg/dl is considered protective against coronary heart disease21. It has been suggested
that hyperlipidemic patient should receive specific medical therapy according to their degree of risk
and serum lipoprotein levels21,22. A high degree of risk has been defined as a personal history of
cardiovascular diseases or two or more major risk factors which include male sex, hypertension,
smoking, diabetes mellitus, obesity, family history of heart disease and low levels of HDL-
cholesterol21,22. The goal of the drug therapy is to bring the serum lipoprotein levels in the desirable
range. However, one should not be over-enthusiastic in lowering plasma lipid levels beyond the
desirable range as hypolipidemia can also have some undesirable effects such as increased
predisposition to certain types of cancer and increased susceptibility to the harmful effects of
endotoxin7. Drug therapy for hyperlipidernia should be supplernentary to dietary therapy and changes
in life style without which it is unlikely to succeed. At present a w’ide variety of lipid lowering agents
with distinct mechanisms of action and pharmacological effects are available. These drugs include
HMG-CoA reductase inhibitors, bile acid binding resins, fibric acid derivatives, nicotinic acid,
probucol and several traditional remedies. Several extensive reviews on the pharmacology of anti-
hyperlipidemic drugs have been published2325. As discussed under the causes of hyperlipidemia,
plasma lipoprotein pattern are not very specific to various primary and secondary disorders. More than
one lipoprotein pattern may occur in a particular disease or condition and similarly several diseases
may produce a common biochemical abnormality in lipid metabolism. From a therapeutic viewpoint
patients with hyperlipidemia usually have one of the following four distinct plasma lipoprotein profiles
(Table V).
Each of these patterns may represent a different disease process and may require a unique therapeutic
approach (Table V).
Common lipid profiles and their management
A) High LDL and normal TG levels
Patients with a high LDL levels usually have an elevated total cholesterol levels and a normal or nearly
normal plasma TG levels. The major primary causes of this lipoprotein pattern include polygenic
hypercholesterolemia, familial combined hyperlipidernia and familial hypercholesterolemia13. While
theexact moleculardefectinthefirst two disorders have not been characterized, familial hyper-
cholesterolemiais due to decreased expressionof hepatic LDL receptors26. Heterozygous type of this
disorder is quite common with an incidence rate of 1 in 500 in general populationwhile the
homozygous type is very rare. A decrease in the expression of hepatic LDL receptors leads to reduced
catabolism of LDL resulting in increased plasma levels. The decreased LDL turnover also leads to
prolonged LDL exposure to the endothelium and increased formation of oxidized LDL particles. These
oxidized LDL particles have a high affinity for macrophage scavenger receptors resulting in their
deposition in the arterial wall and enhanced atherogenesis27. In patients with an elevated LDL levels,
drug therapy is directed at enhancing the expression of LDL receptors which can increase receptor
mediated LDL catabolism. This goal is accomplished by the use of HMG-CoA reductase inhibitors and
bile acid binding resins. HMG-CoA reductase inhibitors such as lovastatin, pravastatin and simvastatin
interfere with cholesterol synthesis by inhibiting HMG-CoA reduclase, the rate limiting enzyme in
cholesterol biosynthesis28. As a result there is a decrease in the hepatic cholesterol synthesis and a
subsequent reduction in the intracellular pool of cholesterol. This leads to a compensatory increase
inthe expression of high affinity LDL receptors on the cell surface resulting in enhanced receptor
mediated clearance of LDL and a further reduction in plasma LDL levels28. Studies have shown that
lovastatin, pravastatin and simvastatin produce a dose-dependent decrease inLDL levels to the extent of
30-40%. They also produce a 15-20% decrease in plasma TG levels and an approximately 10%
increase in plasma HDL levels29,30. HMG-CoA reductase inhibitors appear equally effective in
lowering LDL levels in patients with familial heterozygous hypercholesteroleniia, polygenic
hypercholesterolemia, familial combined hyperlipidemia and other less characterized lipid disorders31.
Bile acid binding resins such as cholestyramine and colestipolbindwithbile acids in the intestinal lumen
and form insoluble complexes resulting in their decreased absorption from the ileum. This interrupts
the enterohepatic circulation of bile acids and leads to their enhanced fecal excretion. In response to the
depletion of bile acid pool, hepatic synthesis of bile acids from cholesterol is stimulated resulting ma
decrease in the pool of intracellular cholesterol. This produces a compensatory increase in the
expression of LDL receptors on hepatocytes which results in an enhanced clearance of LDL and a
further decrease in plasma LDL levels32. Cholestyramine and cholestipol produce a 15-30% decrease in
plasma LDL levels and have been found effective in patients with different genetic causes of primary
hypercholesterolemia31. Majority of patients with primary hypercholesterolemia (except those with
homozygous fanulial hypercholesterolemia) respond well toHMG-CoAreductase inhibitors orbile acid
binding resins. In patients who respond poorly to one of these drugs or have profound elevation inLDL
levels, itis sometimes necessary to combine both approaches. Studies have shown that a combination of
HMG-CoA reductase inhibitorandbileacidbinding resinhave anadditive effectand 50-60% reduction in
LDL levels is commonly achieved with this dual approach33. Probucol is generally considered a second
line drug for the treatment of hypercholesterolemia. Probucol produces a 15-20% decrease in LDL
levels and has no effect on TO levels23. It lowers LDL levels by enhancing its catabolism through the
non- receptor mediated pathways and has no effect on rates of LDL production23. Probucol also has
anti-oxidant properties and it retards the oxidation of lipoproteins25 and thus it may be useful in the
management of atherosclerosis. However, probucol decreases HDL levels by 20-25% by decreasing the
synthesis of apo A-I and A-II and by increasing the activity of cholesterOl ester transfer protein25. This
effect of probucol on HDL levels has limited its use in the management of patients with
hyperlipidemia.
B) High TG and normal LDL levels
An increase in plasma TO levels is usually due to an increased hepatic synthesis and secretion of VLDL
particles. In some cases it could be due to a deficiency or abnormal function of lipoprotein lipase which
results in a decreased clearance of TO- rich lipoproteins13,14. Majority of the cases of
hypertriglyceridemia are due to secondary causes such as excessive dietary fat, increased intake of
simple sugars, alcohol, obesity, pOorlycont.rolled diabetes mellilus, chronic renal failure and drugs like
glucocorticoid, beta blockers or thiazide diuretics8,13,14. It is important to realize that primary and
secondary causes of hypertriglyceridemia can co-exist and secondaiy causes can aggravate primary
hypertriglyceridemia.
The treatment of elevated plasma TO levels is relatively straight forward. . Hypertriglyceridemias are
usually very responsive to weight reduction and nutritional therapy consisting of avoidance of
excessive dietary fats, simple sugars and alcohol34. If the patient is also diabetic; then plasma glucose
levels must be controlled before any other therapy is undertaken. If the response to dietary therapy is
not adequate, then drug therapy should be considered. Drug therapy should also be considered if the
patient has severe hypertriglyceridemia (plasma TO levels greater than 800-1000 mg/dl) or has multiple
risk factors34. Most of the hypertriglyceridemic patients readily respond to fibric acid
derivatives(Gemfibrozil, Bezafibrate, Fenofibrate and Ciprofibrate) or nicotinic acid. Fibric acid
derivatives lower plasma TO level by multiple mechanisms. They activate lipoprotein lipase resulting
in enhanced catabolism of TO-rich lipoprOteins. They also produce a decrease in hepatic TG synthesis
and VLDL secretion35. in addition to their effects on TO metabolism, fibrates also increase HDL levels
by increasing the production of apoprotein A- 1. Studies have shown that fibrates lower plasma TO
levels by 40- 50%, raise HDL levels by 15-30% and decrease LDL levels by 10- 15%36. Elevated TO
levels have been shown to increase insulin production resulting in hyperinsulinemia and insulin
resistance37. Elevated serum insulin concentration can further c hance TO synthesis and VLDL
secretion resulting in a cyck’ of hypertriglyceridemia and hyperinsulinemia37. Recent studies reveal
that when TO levels are lowered with Gcmfibrozil, there is also a concurrent decrease in serum insulin
levels38. Nicotinic acid or niacin is an effective drug for the treatment of both hypertriglyceridemia and
hypercholestemlernia because of its favourable effect on the plasma concentrations of all lipoproteins.
The daily requirement of nicotinic acid as vitamin is 15 rug whereas hypolipidernic effect is seen at
doses over 1000 mg/day25. Nicotinic acid lowers lipoprotein levels by reducing hepatic VLDL produc-
tion39. Since VLDL is partially converted to LDL, inhibition of VLDL production leads to a subsequent
decrease in LDL levels. Nicotinic acid decreases production of apo B-l00 which is a marker for VLDL
and LDL and increases the synthesis of apo A-i which is a marker for HDL. Therapeutic doses of
nicotinic acid decrease plasma TO levels by 25-50%. raise HDL levels by 20- 25% and lower LDL
levels by 20-30%40. Although nicotinic acid has favourable effects on all lipoproteins, many patients
cannot tolerate it because of several adverse effects which include facial flushing, glucose intolerance,
elevations in uric acid and hepatic transaminase levels25. Facial flushing is the most distressing
symptom which is mediated by prostaglandin release andcanbeavoided by starting with a low dose and
increasing the dose gradually, by the use of sustained release formulations or by the use of 325 mg
aspirin 30 minute before taking nicotinic acid34. Glucose intolerance is another side-effect which limits
its usefulness in diabetic patients with hyperlipidemia34.
C) High LDL and high TG levels
Hyperlipidernic patients who have an elevation of both LDL and TO levels are among the most
difficult to treat. They usually show a modest response to weight reduction and avoidance of dietary fat
and cholesterol but often require drug therapy23-25. Nicotinic acid is the drug of first choice in these
patients because it decreases VLDL production and since majority of LDL is derived from VLDL, it
also substantially lowers LDL levels39. Nicótinic acid has no effect on the catabolism of VLDL orLDL.
Unfortunately one of the major cause for an increase in both LDL and TO levels is diabetes mellitus
which may be aggravated by the use of nicotinic acid34. Fibric acid derivatives especially gemfibrozil
has been used in many of the patients with elevated VLDL and LDL levels and it usually normalizes
the TO levels, however, the elevated LDL level often persists36. Another alternative treatment is to
combine fibric acid derivatives with an HMG-CoA reductase inhibitor. This combination has been
shown to lower both plasma TG and LDL levels41 however, there is an increased incidence of myositis
and/or myopathy41 which is a relatively rare side effect when these drugs are used alone. In some
instances reversible rhabdomyolysis has also been reported with use of this combination41. Therefore,
it is advisable to use this combination approach only in carefully selected patients. Creatine kinase
levels should be measured prior to initiation of this combination therapy and eve rv two to three months
during the therapy25. Clearly there is a need for additional agents that can lower both LDL and VLDL
levels without producing the side effects associated with nicotinic acid or the combination of fibric acid
derivatives and HMG-CoA reductase inhibitors.
D) Low HDL with normal or high TG and/or LDL
Low levels of HDL cholesterol may occur as an isolated biochemical abnormality with normal LDL
and VLDL levels and is either familial or due to smoking, physical inactivity or therapy with
androgens42. More commonly low HDL levels are accompanied by an increase in TO and/or LDL
levels and are usually due to secondary factors such as hypertriglyceridernia, obesity and type II
diabetes mellitus13,14. A decrease in HDL levels either alone or in combination with increased TG and
LDL levels is usually associated with an increased risk of coronary heart disease22. The management of
low HDL levels includes life style modifications and drug therapy. Patients should be advised to reduce
caloric intake, maintain ideal body weight, abstain from smoking and exercise regularly42. Exercise not
only helps in achieving the ideal body weight but it also increases insulin sensitivity, lowers serum TO
levels and raises HDL levels43. In selected cases lipid lowering agents that may simultaneously raise
HDL concentrations should be considered and the preferred drugs for this purpose include fibric acid
derivatives and nicotinic acid25. Both fib’rntes and nicotinic acid increase the production of apo A-i
which is the markerfor HDL25,39. Additionally, both of these drugs raise HDL level indirectly due to
their VLDL lowering effect. VLDL normally exchanges its lipids with HDL, the TOs of VLDL move to
HDL and cholesterol esters of HDL shift to VLDL. When VLDL levels is lowered, this exchange
process is slowed and cholesteml esters rernainonHDL and thus HDL concentration is increased35,39.
HMG-CoA reductase inhibitors have also been shown to produce a 8-10% increase in plasma HDL
levels insome studies29-31.
Use of traditional remedies in lowering plasma lipid levels
The plants have been a constant source of medicines throughout the development of civilization. The
revival of interest in the natural products, pharmacology in the recent years is likely to provide cheaper
and more effective drugs44. Several herbal remedies have been traditionally used to lower lipid levels,
amongst which, garlic (Allium sativum) has been the extensively studied. Numerous studies both in
experimental animals and in clinical trials have shown the usefulness of garlic ‘in lowering plasma
lipids45-50. Garlic also retards the oxidation of lipoproteins49. In addition to its multiple medicinal uses,
garlic has also some effects that contribute to a lowering of the cardiovascular risk. These effects
include reduction of blood pressure, inhibition of platelet aggregation, activation of fibrinolysis and
reduction in plasma and blood viscosity45,47. Considering these effects, it is likely that garlic may be
useful in the primaiy and secondaiy prevention of atherosclerosis. Several other plants have also been
found to exhibit hypolipidemic effect. For example, a commonly used condiment, onion (Allium sepa)
is known to exert a lipid lowering effect51. Ginko bioloba is widely available in the form of a
standardized extract and is primarily used for cerebral insufficiency due to aging52 but it is also
effective in lowering plasma lipids53. Some other plants, such as Gymnema sylvestra and Pterocarpus
marsupium has been shown to be effective in lowering plasma lipids54-56. Recently a traditional recipe
of Pakistan containing several different plant constituents including fruits of prunus bokharensis (Plum)
and Berberis aristata (Zarshik) and the flowers of Nympaca lotus(Water lily) and Rosa indica (White
rose) was studied by a research team at the Ayub Medical College, Abbottabad57 and it was found to
have lipid lowering effect. Interestingly, one plant (Berberis anstata) of this recipe was also found to
have a hepatoprotective effect in a recent study in our lab58. Hyperlipidemia is usually accompanied by
several other cardiovascular disorders such as hypertension and ischemic heart disease. It is quite
common that patients receive multiple drugs in addition to the anti-hyperlipidemic therapy. Therefore,
in such cases, the characteristics of these drugs should be taken into account. Beta-adrenoceptor
blockers have been extensively used in the treatment of hypertension and ischemic heart disease
whereas, thiazide diuretics are widely used in the management of hypertension. Both classes of drugs
have been shown to disturb the lipid profile8 which may negate their useful effects on cardiovascular
system. On the other hand, calcium ‘channel blockers which are also widely used in hypertension and
ischemic heart diseases are devoid of such side-effects. Rather, they have been shown to have a
beneficial effect by lowering plasma lipid levels59. Interestingly, calcium channel blockers are
abundantly present in medicinal plants. Recently we have shown that several plants, ‘which have been
traditionally used to treat hypertension, contain calcium channel blocker like substances60-65. Such
examples include Artemisia scoparia (Jhan), Artemesia absinthiuni (Afsanteen), Cyperus scariosus
(Nagar motha), Cuscuta reflexa (Akasbel), Daucus carota (Carrot), Moringa oleifera (Sohajnan) and
Rubia cordifolia (Manjit) Thus, it is possible that these plants may also have lipid lowering properties
and hence need tobe studied furtherfor this activity. Pakistan is rich in the herbal wealth and well over
70% of country\'s population rely on traditional remedies which mainly consists of plant constituents66.
However, these remedies have not been tested scientifically because of the lack of proper expertise and
there is a great potential for working in this field.
Conclusion 
High LDL and low HDL levels are major risk factors for coronaty heart disease whereas,
hypertnglyceridemia in combination with low HDL or high LDL predisposes to enhanced
atherogenesis. Nutritional counselling and drug therapy for hyperlipidemia can significantly decrease
cardiovascular mortality and morbidity. The drug therapy in patients with hyperlipidemia should be
individualized with careful consideration of secondary causes and other risk factors, plasma lipoprotein
profile, patient’s life style, anticipated side-effects, desired benefits and cost- effectiveness. The patients
should be encouraged to quit smoking, improve their dietary habits, attain ideal body weight and
participate in appropriate exercise programmes. Serum lipid levels should be regularly monitored and
an effort should be made to control hypertension, diabetes and other associated diseases in these
patients. While the major focus of our physicians is on allopathic medicines, it should be borne in mind
that a substantial proportion of ourpatient population use traditional remedies, which should not be
ignored.
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